Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans-Jurgen Stellbrink

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
AIDS (London, England)|July 20, 2002
Pneumocystis carinii pneumonia after the discontinuation of secondary prophylaxisOlaf Degen, Jan ven Lunzen, Matthias A Horstkotte, et al.
Infectious Diseases and Therapy|August 1, 2022
HIV DNA Sequencing to Detect Archived Antiretroviral Drug ResistanceAnna Maria Geretti, Jose Luis Blanco, Anne Genevieve Marcelin, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 4, 2005
Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapyMikulas Popovic, Klara Tenner-Racz, Colleen Pelser, et al.
The New England Journal of Medicine|May 11, 2022
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionSorana Segal-Maurer, Edwin DeJesus, Hans-Jurgen Stellbrink, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 30, 2007
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005Bruno Hoen, David A Cooper, Fiona C Lampe, et al.
The Lancet. HIV|June 7, 2020
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trialsChloe Orkin, Edwin DeJesus, Paul E Sax, et al.
Science (New York, N.Y.)|November 6, 2010
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation, Florencia Pereyra, Xiaoming Jia, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
AIDS (London, England)|July 20, 2002
Pneumocystis carinii pneumonia after the discontinuation of secondary prophylaxisOlaf Degen, Jan ven Lunzen, Matthias A Horstkotte, et al.
Infectious Diseases and Therapy|August 1, 2022
HIV DNA Sequencing to Detect Archived Antiretroviral Drug ResistanceAnna Maria Geretti, Jose Luis Blanco, Anne Genevieve Marcelin, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 4, 2005
Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapyMikulas Popovic, Klara Tenner-Racz, Colleen Pelser, et al.
The New England Journal of Medicine|May 11, 2022
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionSorana Segal-Maurer, Edwin DeJesus, Hans-Jurgen Stellbrink, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 30, 2007
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005Bruno Hoen, David A Cooper, Fiona C Lampe, et al.
The Lancet. HIV|June 7, 2020
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trialsChloe Orkin, Edwin DeJesus, Paul E Sax, et al.
Science (New York, N.Y.)|November 6, 2010
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation, Florencia Pereyra, Xiaoming Jia, et al.
Pageof 1